Importante discussão sobre o tratamento com Imuno-Oncológicos em pacientes com doença auto-imune ativa.

Article Highlights

• Patients with autoimmune conditions are largely excluded from immunotherapy clinical trials, and clinicians treating patients outside of the trial setting may feel some reluctance to introduce these therapies in this population.
• Retrospective reviews and case reports provide support that checkpoint inhibitor therapy demonstrates evidence not only of efficacy but also of safety and tolerability in patients with preexisting autoimmune conditions.
• Practitioners should carefully weigh the risks and benefits of checkpoint inhibitor therapy in this population. After informed discussions prior to treatment, patients should be carefully monitored for autoimmune side effects.
• Leia a materia completa.